Evaluating APP-based Management Using the Yueya Mini-Program and WeChat to Improve Quality and Outcomes of Maintenance Hemodialysis in Adults with End Stage Renal Disease

What this Trial Is About

Researchers are evaluating whether using the Yueya mini-program and WeChat to manage care can improve the quality of blood purification therapy and outcomes for patients undergoing maintenance hemodialysis MHD. Many MHD patients face negative outlooks due to their illnesses and complications, which can affect their quality of life and prognosis. This trial aims to see if personalized guidance via an app can help improve treatment compliance, quality of life, and patient prognosis. Participants will be randomly assigned to either an APP management group or a non-APP management group. The APP group will receive individualized, continuous support through the Yueya mini-program and WeChat, including health education, diet and exercise guidance, medication supervision, condition monitoring, and real-time feedback tailored to their age, gender, primary disease, and complications. The control group will receive routine care without the app-based guidance. During the study, researchers will monitor clinical and laboratory indicators, record cardiovascular events, deaths, hospitalizations, and assess quality of life and treatment compliance over about one year. The primary outcomes include mortality rate, hospitalization rate, kidney disease quality of life, and incidence of cardiovascular events. The study aims to strengthen quality control in hemodialysis units and improve patient management and prognosis.

Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy